Article Sidebar

PDF
Date Published: 15/01/2024
Abstract Views: 202
Views PDF: 164
DOI: https://doi.org/10.51298/vmj.v534i1.8033
Issue
Vol. 534 No. 1 (2024)
Section
Các bài báo
How to Cite
Cấn, X. H. ., & Trần , T. C. . (2024). EFFICACY AND SAFETY OF PACLITAXEL CARBOPLATIN IN THE TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER. Vietnam Medical Journal, 534(1). https://doi.org/10.51298/vmj.v534i1.8033

EFFICACY AND SAFETY OF PACLITAXEL CARBOPLATIN IN THE TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER

Xuân Hạnh Cấn, Thị Chung Trần

Main Article Content

Abstract

Objectives: To evaluate the results and safety of second-line treatment with Paclitaxel-carboplatin regimen in patients with stage IIIB-IV non-small cell lung cancer. Methods: A cross-sectional descriptive study combining retrospective and prospective with longitudinal follow-up on 42 patients with stage IIIB-IV non-small cell lung cancer receiving second-line paclitaxel-carboplatin regimen at National Lung Hospital. The implementation period is from January 2016 to June 2019. Results: The average age of the patients was 56 ± 3.1, the female/male ratio was 2.5/1, stage IV patients accounted for 66.7%. Overall response rate (ORR) was 42.8%, disease control rate (DCR) was 83.3%. Progression-free survival 2 (PFS2) had a median value of 6.4 months (range 3.1 – 10.1 months). In the course of treatment, the patient had good tolerance, mild toxicity (grade 1, 2) and was uncommon in the hematopoietic and non-haematopoietic systems. Conclusion: Patients with stage IIIB-IV NSCLC who received second-step treatment with paclitaxel-carboplatin chemotherapy regimen had a high overall response rate and disease control rate, prolonged progression-free survival, acceptable safety.

Article Details

References

1. Sung H, Ferlay J, Siegel R.L et al (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 71(3), 209-249.
2. Thandra K.C, Barsouk A, Saginala K et al (2021). Epidemiology of lung cancer. Contemp Oncol (Pozn), 25(1), 45-52.
3. König D, Savic Prince S and Rothschild S.I (2021). Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations. Cancers (Basel), 13(4).
4. Mok T.S, Wu Y.L, Ahn M.J et al (2017). Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med, 376(7), 629-640.
5. Kogure Y, Iwasawa S, Saka H et al (2021). Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial. Lancet Healthy Longev, 2(12), e791-e800.
6. Nguyễn Bá Đức (2010). Báo cáo sơ bộ kết quả thực hiện dự án quốc gia về phòng chống ung thư giai doạn 2008-2010. Tạp chí ung thư học Việt Nam,, 1, 24-25.
7. Nguyễn Thị Thanh Huyền (2007). Đánh giá kết quả điều trị ung thư phổi không phải tế bào nhỏ giai đoạn IIIB- IV phác đồ Docetaxel- Carboplatin tai bệnh viện K, Luận Văn Thạc Sỹ Chuyên Ngành Ung Thư, Đại học Y Hà Nội.
8. Lê Thu Hà (2008). Đánh giá hiệu quả điều trị ung thư phổi không phải tế bào nhỏ giai đoạn IIIB - IV phác đồ Paclitaxel - Carboplatin tại bệnh viện Ung bướu Hà Nội, Luận Văn Thạc Sỹ Chuyên Ngành Ung Thư, Đại học Y Hà Nội.
9. Urata Y, Katakami N, Morita S et al (2016). Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L. J Clin Oncol, 34(27), 3248-57.
10. Gatzemeier U, von Pawel J, Gottfried M et al (2000). Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol, 18(19), 3390-9.